Dash Bio raises $30M Series A to accelerate bioanalysis turnaround times

Dash Bio, a company building automation infrastructure for bioanalysis, announced it has raised $30 million in Series A financing led by Oak HC/FT, with participation from existing investors Freestyle Capital and Swift Ventures.¹ The round brings the Waltham, Massachusetts-based company's total funding to $47.5 million.¹

What problem is Dash Bio addressing?

Bioanalysis, the lab-based measurement of a drug's safety and efficacy in preclinical and clinical samples, is described by the company as a $5 billion market that still runs largely on manual labor and paper-based records, often returning data months after samples are submitted.¹ Independent market analysis puts the sector at a similar scale, valuing it at roughly $4.8 billion in 2024.²

Grand View Research attributes much of this growth to increasing complexity of therapeutics and a broader industry shift toward outsourcing testing services, noting that the large-molecule segment, covering monoclonal antibodies, therapeutic proteins, and gene therapies, is projected to expand at the fastest rate as biologics and biosimilars pipelines continue to grow.²

Dash Bio has built a 24,000-square-foot Good Laboratory Practice facility that pairs robotics with a proprietary laboratory operating system across assay workflows including enzyme-linked immunosorbent assay, Meso Scale Discovery, quantitative polymerase chain reaction, digital droplet PCR, and liquid chromatography-mass spectrometry.¹ The company states this approach removes much of the manual labor and queuing time associated with traditional bioanalysis contract research organizations, offering full pricing transparency, end-to-end digital traceability, and preclinical sample results returned in days rather than months.¹ This kind of regulated bioanalysis work is governed by FDA's bioanalytical method validation guidance, which establishes the quality and reliability standards labs must meet.³

How has the platform been received commercially?

Since launching go-to-market efforts roughly nine months ago, Dash Bio has signed contracts with more than 30 customers, including four top-15 global pharmaceutical companies.¹ The company states that customer feedback has consistently pointed to speed and pricing transparency as decisive factors in choosing Dash Bio over incumbent providers.¹

What did company and investor leadership say?

Dave Johnson, co-founder and CEO of Dash Bio, said, "Sponsors and patients can't wait. We built Dash on a deep conviction: the pace of drug development should be set by the science, not by queues and legacy process. Our goal is to push deliverable timelines to the very limits of the underlying chemistry, physics, and biology. Everything about how we operate, from our tech-first approach to our transparent, fixed pricing, is built to serve that goal, and ultimately to get medicines to patients faster."¹ Andy Smith, partner at Oak HC/FT, said, "In less than two years, the Dash team has built a GLP-compliant, fully automated bioanalysis platform that the industry's largest drug developers are already adopting. The team's background architecting the digital and automation infrastructure at Moderna during one of the most consequential scale-ups in modern history brings a playbook and level of experience to productizing and scaling infrastructure for science that very few founders in this space can match."¹

What happens next?

Dash Bio said the new funding will support continued scaling of commercial operations, expansion of its assay menu and laboratory capacity, entry into new service categories, and further development of its proprietary software platform.¹ The company was founded by Dave Johnson (CEO), Ander Tallett (COO), and Ely Porter, PhD (CSO).¹

References

1. Dash Bio raises $30M Series A to accelerate drug development timelines. News release. Dash Bio; August 2026. Accessed August 4, 2026.
2. Bioanalytical testing services market size, share and trends analysis report, 2025-2033. Grand View Research; 2026. Accessed August 4, 2026. https://www.grandviewresearch.com/industry-analysis/bioanalytical-testing-services-market
3. US Food and Drug Administration. Bioanalytical method validation: guidance for industry. Center for Drug Evaluation and Research; May 2018. Accessed August 4, 2026. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf